About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need

Demodex Blepharitis A highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Ocular Rosacea A common inflammatory condition of the eyelid and eyelid margin

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-04 An investigational treatment for ocular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information

Investors Overview

News & Presentations

Events

Financials

Publications Corporate Governance

Stock Information

Other Resources

Our Story Our Leadership Our Values Our Responsibility Medical Affairs

Demodex Blepharitis Lyme Disease Ocular Rosacea

XDEMVY® (lotilaner ophthalmic solution) 0.25%

Pipeline Overview TP-04 TP-05

Investors Overview

News & Presentations

Events

Financials

Publications Corporate Governance

Stock Information

Other Resources

Careers

Publications

Cornea

April 2023

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)

View Article

Eye

March 2023

Clinical Diagnosis and Management of Demodex Blepharitis: The Demodex Expert Panel on Treatment and Eyelid Health (DEPTH)

View Article

Clinical Ophthalmology

February 2023

Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex Blepharitis

View Article

Clinical Ophthalmology

September 2022

Psychosocial Impact of Demodex Blepharitis

View Article

Ocular Immunology and Inflammation

August 2022

Treatment of Demodex Blepharitis: A Prospective, Randomized, Controlled,  Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25%  Eyedrops to Vehicle

View Article

Contact Lens & Anterior Eye

August 2022

Safety and Efficacy of Lotilaner Ophthalmic Solution, 0.25% for the Treatment of Blepharitis Due to Demodex Infestation: A Randomized, Controlled, Double-Masked Clinical Trial

View Article

Clinical Ophthalmology

April 2022

The Prevalence of Demodex Blepharitis in US Eye Care Clinic Patients as Determined by Collarettes: A Pathognomonic Sign

View Article

Journal of Ophthalmology

September 2021

Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study

View Article

Our Terms of Use and Privacy Policy have changed. 
By clicking accept, you agree that you have read and will abide by these new terms.

Reject Accept